Ability of brain natriuretic peptide tests and homocysteine to exclude congestive heart failure

Mira Barak, Jorge E. Schliamser, Nisan Yaniv, Paul Froom*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Among the most promising tests for early detection of congestive heart failure (CHF) are brain natriuretic peptides (BNPs), but it is unclear if homocysteine can aid in differentiating those with and without disease. We attempt to use a combination of tests to reduce the need for echocardiography without missing any cases of CHF. We compared 50 CHF patients with an ejection fraction of less than 60%, to 100 patients with non-specific symptoms but with a normal echocardiogram. After setting sensitivity at 100%, specificities for BNP, amino-terminal probrain natriuretic peptide (NT-pro BNP), and homocysteine were 34%, 28% and 36% respectively. Combinations of two tests if ho-mocysteine was included increased the specificity to 56%. The AUC for BNP and NT-proBNP were not significantly different (92.8 and 95.9, respectively) whereas the AUC for BNP and NT-proBNP tests were superior to homocysteine (83.2). Compared with performing echocardiography in all patients, savings were dependent on the pretest probability. At a 1% pretest probability of CHF, savings were 44.5% while using a combination of NT-proBNP with homocysteine test. Homocysteine can be used in combination with either of the BNPs to decrease costs of early detection of CHF.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalOpen Clinical Chemistry Journal
Volume3
DOIs
StatePublished - 2010
Externally publishedYes

Keywords

  • Brain natriuretic peptide
  • Comparison
  • Congestive heart failure
  • Costs
  • Homocysteine
  • NT-proBNP

Fingerprint

Dive into the research topics of 'Ability of brain natriuretic peptide tests and homocysteine to exclude congestive heart failure'. Together they form a unique fingerprint.

Cite this